Replies to post #7243 on Nexus Energy Services Inc (IBGR)

[tripil7z]

Bayer to buy PHAR in my opinion.

[senator]

PharmStar Pharmaceuticals Addresses Bayer Aspirin Reformulation
Pharmstar Pharms (PC) (USOTC:PHAR)
Intraday Stock Chart
Today : Wednesday 25 May 2011


PharmStar Pharmaceuticals, Inc. (PINKSHEETS: PHAR) (the "Company"), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today published the following statements in response to the recent announcement (May 23, 2011) from Bayer AG regarding its new product, "Bayer Advanced Aspirin."
PharmStar management stated that it believes Aquaprin, the signature product from PharmStar Pharmaceuticals, Inc., will be the fastest acting analgesic on the market.

Bayer introduced a reformulation of its tablet earlier this week, and the research is telling. Bayer has created a tablet that now begins working in 16 minutes, and reaches "meaningful pain relief" in 49 minutes. Compare that to Aquaprin, a liquid derivative of aspirin, which begins working in less than 3 minutes, and eases a headache in less than 10 minutes. Aquaprin is also non-acidic, acts as an antacid, and is easy on the stomach -- unmatched by any aspirin tablet on the market.

PharmStar CEO Howard Phykitt stated, "We have always known tablets take too much time to start working. It is the nature of tablet forms of medicine, and is the reason that I developed Aquaprin and related line extension products. Improving the therapeutic effectiveness to 49 minutes is a good start, but Aquaprin reaches that level in less than 10 minutes. Not to mention this new Bayer aspirin is still acidic, only delivering about 45-50% of the medicine into the bloodstream. Aquaprin is not acidic, but is an antacid, and delivers 100% of the medicine. So, reducing the time that you have to endure a headache from 100 minutes down to 49 minutes is good news I guess, but it means little to those that can't let an acidic tablet sit on their stomach even that long."

Mr. Phykitt continued, "This announcement by Bayer is a clear signal that the analgesic market is now more demanding and one that can be supplied with faster pain relief products. By Bayer's own admission, its product is now better known for preventing heart attacks than as a pain reliever. I believe Bayer is trying to remind consumers its aspirin also works well for killing pain, and that its new product works more quickly than its standard aspirin."

"I am happy that Bayer is re-educating people about the value of aspirin as a pain reliever, as it has been valuable for thousands of years," concluded Mr. Phykitt. "Wait until those same people experience aspirin at its best, when our liquid derivative hits the market. We are not doing the same thing over and over, but really advancing the great value of aspirin to a superior level."